Ghana, indeed is very rich. Otherwise the level of waste in state institutions would have been enough to render the country bankrupt.
When Goil rebranded, it embarked upon awareness creation, because it was very necessary. The reason is not farfetched, it is because Goil is in competition with more than 15 Oil Marketing Companies (OMCs) and so the company must be position as the preferred choice for motorists and car owners.
The Food and Drugs Authority (FDA) formerly the Food and Drugs Board (FDB) was established in August 1997 under the Food and Drugs Law, 1992 (PNDCL 305B). It is the National Regulatory Authority mandated by the public Health Act, 2012 (Act 851) to regulate food, drugs, food supplements, herbal and homeopathic medicines, veterinary medicines, cosmetics, medical devices, household chemical substances, tobacco and tobacco products.
The objective of the Authority is to provide and enforce standards for the sale of food, herbal medicinal products, cosmetics, drugs, medical devices and household chemical substances.
Curiously, in our view FDA, has over the years struggled to meet any of its set objectives. The country is flooded with fake products, including medicine.
FDA, is supposed to have officers at all the country’s points of entry, but on a daily basis, we are inundated with fake or substandard product.
Intriguingly, after spending so much to rebrand, the Authourity has gone to bed, not because they want to, but it was not necessary to begin with.
They is nothing else to be done after the launch, which attracted high profile personalities, including the first lady, Rebecca Akufo-Addo and the minister of Health, Dr. Agyeman Kweku Manu.
According Mrs Akufo-Addo, in a keynote address, she charged the authority “not to re-brand for re-branding sake, but ensure that its rebranding was purposeful and in line with its mandate to the Ghanaian people.
FDA, should have used the money they wasted on this venture to embark on awareness creation about the dangers of illicit drugs.
The money could equally have been used to procure state the art of equipment to improve the operations of the authourity.
This newspaper is disappointed in the management of FDA, especially the Chief Executive Officer (CEO) Mrs Delese Darko, who should concern herself about leaving a legacy, worthy of praise and adoration, as her predecessors have.